Octavio Marquez - 30 Jan 2023 Form 4 Insider Report for DIEBOLD NIXDORF, Inc (DBD)

Role
President and CEO, Director
Signature
Jonathan B. Leiken, Attorney-in-fact for Octavio Marquez
Issuer symbol
DBD
Transactions as of
30 Jan 2023
Net transactions value
-$4,754
Form type
4
Filing time
01 Feb 2023, 17:03:25 UTC
Previous filing
12 May 2022
Next filing
07 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DBD Common Shares Tax liability $4,754 -2,067 -0.63% $2.30* 323,652 30 Jan 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DBD Non-Qualified Stock Option 9,327 30 Jan 2023 Common Shares 9,327 $11.96 Direct F3
holding DBD Non-Qualified Stock Option 33,843 30 Jan 2023 Common Shares 33,843 $4.08 Direct F3
holding DBD Non-Qualified Stock Option 19,786 30 Jan 2023 Common Shares 19,786 $18.75 Direct F3
holding DBD Non-Qualified Stock Option 37,996 30 Jan 2023 Common Shares 37,996 $26.60 Direct F3
holding DBD Non-Qualified Stock Option 16,388 30 Jan 2023 Common Shares 16,388 $27.39 Direct F4
holding DBD Non-Qualified Stock Option 22,735 30 Jan 2023 Common Shares 22,735 $32.33 Direct F4
holding DBD Non-Qualified Stock Option 15,885 30 Jan 2023 Common Shares 15,885 $34.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld pursuant to exercise of tax withholding right under the 2017 Equity and Performance Incentive Plan - Restricted Share Award
F2 Number includes restricted stock units.
F3 Granted under the 2017 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.
F4 Granted under the 1991 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.